Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 21, 2022 16:05 ET | Source: Sight Sciences, Inc.

Sight Sciences to Participate in the Upcoming Citi Virtual Healthcare Conference

MENLO PARK, Calif., Feb. 21, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
February 17, 2022 08:00 ET | Source: Sight Sciences, Inc.

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

MENLO PARK, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
January 10, 2022 05:50 ET | Source: Sight Sciences, Inc.

Sight Sciences Announces Preliminary Unaudited Fourth Quarter and Full Year 2021 Financial Results

MENLO PARK, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
December 22, 2021 08:00 ET | Source: Sight Sciences, Inc.

Sight Sciences Receives FDA 510(k) Clearance of the TearCare® System for Treatment of Meibomian Gland Dysfunction (MGD), the Leading Cause of Dry Eye Disease

MENLO PARK, Calif., Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
November 18, 2021 16:05 ET | Source: Sight Sciences, Inc.

Sight Sciences to Participate in the Upcoming Piper Sandler Annual Healthcare Conference

MENLO PARK, Calif., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
November 17, 2021 08:00 ET | Source: Sight Sciences, Inc.

Microinvasive Glaucoma Surgery with the OMNI® Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

MENLO PARK, Calif., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
November 10, 2021 16:05 ET | Source: Sight Sciences, Inc.

Sight Sciences Reports Third Quarter 2021 Financial Results

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
November 10, 2021 16:04 ET | Source: Sight Sciences, Inc.

Sight Sciences Announces FDA Authorization for the PRECISION Trial, a Groundbreaking Three-Arm Randomized, Controlled IDE Trial of Canal Viscodilation in Combination with Cataract Surgery in Adults with Primary Open-Angle Glaucoma (POAG)

MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on creating innovative solutions intended to transform standards of...
October 27, 2021 16:05 ET | Source: Sight Sciences, Inc.

Sight Sciences to Report Third Quarter 2021 Financial Results on November 10, 2021

MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) today announced it will report financial results for the quarter ended September 30, 2021 after the market...
October 20, 2021 08:00 ET | Source: Sight Sciences, Inc.

Sight Sciences Announces TearCare® Clinical Data Published in Cornea

MENLO PARK, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT), a growth-stage medical device company focused on addressing the underlying causes of the world's most...